Pharmaceutical Combination Products
Master the regulatory complexities of drug-device combination products with integrated strategies spanning EU MDR, pharmaceutical legislation, and FDA frameworks to achieve efficient market authorization.
Overview
Pharmaceutical combination products — devices that incorporate or are combined with a medicinal substance — represent one of the most complex areas in medical device and pharmaceutical regulation. Products such as drug-eluting stents, pre-filled syringes, metered-dose inhalers, and transdermal drug delivery patches must satisfy the requirements of both device and pharmaceutical regulatory frameworks simultaneously. The regulatory classification and submission pathway depend on the primary mode of action (PMOA) of the combined product, which determines whether it falls principally under the medical device or medicinal product regulatory regime and which authority or notified body leads the conformity assessment.
Swiss MPC brings deep expertise in both the medical device and pharmaceutical regulatory domains, enabling us to guide manufacturers through the unique challenges of combination product regulation. Under the EU MDR, Article 117 and Annex I GSPR requirements govern the device constituent of drug-device combinations, while the pharmaceutical component remains subject to Directive 2001/83/EC and the relevant competent authority or EMA review. In the United States, the FDA Office of Combination Products assigns lead center responsibility based on PMOA, and manufacturers must comply with 21 CFR Part 4 current good manufacturing practice requirements covering both constituent parts.
Our consultants have direct experience supporting combination product programs across the full spectrum of product types — from integral combinations where the device and drug form a single entity, to non-integral combinations where the device is packaged or co-marketed with a separately authorized medicinal product. We understand the procedural requirements for obtaining Notified Body Opinions (NBOp), coordinating with competent authorities and the EMA, and structuring submissions that satisfy both device and pharmaceutical reviewers without duplication or contradiction.
Whether you are developing a novel drug-device combination, adapting an existing device platform to deliver a new therapeutic agent, or navigating post-market changes to an authorized combination product, Swiss MPC provides the integrated regulatory strategy needed to align device and pharmaceutical workstreams, manage authority interactions, and achieve market authorization across the EU and the United States.
Challenges in Combination Product Regulation
Primary Mode of Action Determination
Determining the PMOA of a combination product is the foundational regulatory decision, yet it is often technically complex and subject to differing interpretations between jurisdictions. An incorrect PMOA determination can route the product into the wrong regulatory pathway, requiring costly redirection. The PMOA assessment must consider the principal mechanism by which the product achieves its intended purpose, supported by scientific justification that withstands scrutiny from both device and pharmaceutical authorities.
Dual Regulatory Framework Coordination
Combination products must satisfy requirements from two distinct regulatory regimes that use different terminology, evidence expectations, and review timelines. Under EU MDR, the device constituent must meet all applicable General Safety and Performance Requirements (GSPRs), while the medicinal substance is assessed under pharmaceutical legislation. Coordinating these parallel workstreams — ensuring consistency in risk-benefit analysis, labeling, and clinical data — without creating conflicting documentation demands careful planning and cross-functional expertise.
Notified Body Opinion and Authority Consultation
For EU combination products where the device is the principal mode of action, the notified body must seek an opinion from a competent authority or the EMA on the quality and safety of the medicinal substance (the Notified Body Opinion, or NBOp). This consultation process adds significant time to the conformity assessment timeline and introduces an additional reviewing authority whose expectations must be anticipated and addressed in the dossier. Delays in the NBOp process are a common source of overall program delay.
Integral vs. Non-Integral Classification
The EU MDR distinguishes between integral combination products (where the device and medicinal substance form a single integrated product, such as a drug-eluting stent) and non-integral combinations (where the device is intended for use with a specific medicinal product but they are not physically combined, such as a companion injection device). This distinction affects the regulatory pathway, the applicable conformity assessment procedures, and the documentation structure. Misclassification between integral and non-integral status can lead to fundamental errors in submission strategy.
Cross-Jurisdictional Divergence Between EU and FDA
The EU and FDA frameworks for combination products differ substantially. The EU applies Article 117 of the MDR and pharmaceutical Directive 2001/83/EC, routing products through either device or pharmaceutical pathways based on PMOA. The FDA uses a combination product framework under 21 CFR Part 3 for designation and 21 CFR Part 4 for cGMP requirements, assigning a lead center (CDER, CBER, or CDRH) based on PMOA. These divergent systems mean a product may follow fundamentally different regulatory pathways in the EU and US, requiring parallel but distinct submission strategies.
Our Combination Product Regulatory Approach
Product Characterization and PMOA Assessment
We begin with a thorough characterization of the combination product, analyzing the mechanism of action of both the device and medicinal substance constituents to determine the PMOA. This assessment draws on the product design intent, pharmacological and mechanical action profiles, clinical evidence, and applicable regulatory guidance from the EU and FDA. We prepare a formal PMOA justification document that serves as the foundation for all subsequent regulatory pathway decisions and can withstand challenge during authority review.
Regulatory Pathway Mapping and Classification
Based on the PMOA determination, we map the applicable regulatory pathway in each target market. For the EU, this includes determining whether the product is regulated primarily as a medical device under the MDR (with NBOp for the drug constituent) or as a medicinal product under Directive 2001/83/EC (with notified body conformity assessment for the device constituent). For the FDA, we advise on Request for Designation (RFD) strategy and lead center assignment. We also classify the product under the relevant device classification rules and identify all applicable GSPR, pharmaceutical, and harmonized standard requirements.
Integrated Submission Strategy Development
We develop a comprehensive submission strategy that coordinates the device and pharmaceutical documentation streams. This includes defining the technical file or Common Technical Document (CTD) structure, mapping the evidence requirements for both constituents, identifying shared and constituent-specific testing programs, and establishing a unified risk management approach that addresses the combination product as a whole. The strategy explicitly plans for the NBOp consultation process and its timeline impact on the overall program schedule.
GSPR Compliance and Technical Documentation
For the device constituent, we ensure full compliance with applicable GSPRs from Annex I of the EU MDR, including biocompatibility of the device in contact with the medicinal substance, drug-device interaction and compatibility testing, container closure integrity (for pre-filled delivery systems), dose accuracy and delivery performance, and human factors engineering for the combined product. We structure the technical documentation to demonstrate compliance with both device-specific and combination product-specific requirements in a manner that facilitates the NBOp consultation.
Authority Engagement and NBOp Management
We prepare and manage the NBOp process, including drafting the medicinal substance dossier sections required by the consulting competent authority or EMA, anticipating questions based on our experience with prior NBOp consultations, and coordinating responses between the manufacturer, the notified body, and the pharmaceutical authority. For FDA submissions, we support pre-submission meeting preparation with the assigned lead center and coordinate any inter-center consultations required for the combination product review.
Lifecycle Management and Post-Market Obligations
Combination products have unique post-market obligations reflecting their dual nature. We establish post-market surveillance programs that cover both the device performance and the medicinal substance safety profile, including adverse event reporting that satisfies both device vigilance and pharmacovigilance requirements. We also advise on change management procedures for combination products, where modifications to either constituent may trigger regulatory consequences under both device and pharmaceutical frameworks, requiring coordinated variation or supplement submissions.
Combination Product Deliverables
- Primary mode of action (PMOA) assessment report with scientific justification
- Combination product classification and regulatory pathway determination
- Integrated regulatory roadmap covering device and pharmaceutical workstreams
- GSPR compliance matrix for the device constituent under EU MDR Annex I
- Notified Body Opinion (NBOp) dossier preparation and consultation support
- FDA Request for Designation (RFD) documentation and lead center strategy
- Drug-device interaction and compatibility testing strategy
- Technical documentation or CTD module structure for combination products
- Integrated risk management file addressing the combined product
- Post-market surveillance plan covering device vigilance and pharmacovigilance
- Change management procedures for combination product lifecycle modifications
- Authority interaction support for NBOp consultations and FDA inter-center reviews
Applicable Standards & Regulations
EU MDR 2017/745 — Article 1(8), (9) and Article 117
The EU MDR provisions governing combination products. Article 1(8) and 1(9) define the scope for devices incorporating medicinal substances, distinguishing integral from non-integral combinations. Article 117 amended Directive 2001/83/EC to require notified body conformity assessment of the device constituent when the medicinal product is the PMOA. Together, these provisions establish the dual-pathway framework for combination products in the EU.
Directive 2001/83/EC (as amended)
The EU pharmaceutical legislation governing medicinal products for human use. For combination products where the medicinal substance is the PMOA, the product is authorized as a medicinal product under this Directive, with the device constituent subject to conformity assessment by a notified body. The Directive requirements for quality, safety, and efficacy of the drug component apply in addition to device-specific requirements.
FDA 21 CFR Part 3 and Part 4
The US federal regulations governing combination products. Part 3 establishes the Office of Combination Products and the process for product designation and lead center assignment based on PMOA. Part 4 defines current good manufacturing practice (cGMP) requirements for combination products, requiring compliance with both device QSR (21 CFR 820) and drug cGMP (21 CFR 210/211) or biological product regulations as applicable to each constituent part.
ISO 11040 Series (Pre-filled Syringes)
International standards for pre-filled syringe systems, covering glass barrels, plastic containers, needle-based and needle-free injection systems, and delivery systems for use with pre-filled syringes. These standards define dimensional requirements, performance testing, and quality requirements critical for pre-filled syringe combination products where the device delivery system must perform reliably with the contained medicinal substance.
ISO 20072:2009 (Aerosol Drug Delivery Devices)
International standard providing requirements and test methods for aerosol drug delivery device systems, including metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). Covers dose delivery, spray characterization, device functionality, and patient interface requirements relevant to inhaler-type combination products where the device component is integral to therapeutic delivery.
ISO 14971:2019 (Risk Management)
The international standard for risk management of medical devices. For combination products, ISO 14971 must be applied to address risks arising from the device constituent, the medicinal substance, and critically, the interactions between them — including drug-device compatibility, dose delivery accuracy, and failure modes that may affect both device performance and therapeutic efficacy or patient safety.
MDCG 2021-22 (Guidance on MDR Article 117)
Medical Device Coordination Group guidance providing practical interpretation of the Article 117 amendments to Directive 2001/83/EC. Addresses the consultation procedure between notified bodies and competent authorities or the EMA, the documentation requirements for the device constituent, and the procedural steps for obtaining the Notified Body Opinion during the medicinal product marketing authorization process.
EMA Guideline on Quality of Combination Products
European Medicines Agency guidance addressing quality documentation requirements for combination products submitted through the pharmaceutical (centralized or national) authorization pathway. Covers the device constituent quality data expected within the CTD Module 3, including device description, design verification and validation, manufacturing process, and performance specifications relevant to drug delivery.
Frequently Asked Questions
Related Services
Regulatory Strategy & Compliance
Regulatory roadmaps, pathway identification, MDR/IVDR transition, and notified body interaction
Learn moreTechnical Documentation & CE Marking
Technical files, Design History Files, EU MDR/IVDR submissions, and FDA 510(k)/PMA
Learn moreClinical Affairs
Clinical Evaluation Reports, literature reviews, PMCF planning, and data collection
Learn moreReady to Accelerate Your Regulatory Compliance?
Schedule a free consultation with our senior regulatory experts